<p>根据最近向证券交易委员会（SEC）提交的 13F 文件，Banque Transatlantique SA 在第三季度将其在爱德华生命科学公司（NYSE:EW - 免费报告）的持股比例削减了 32.6%。该机构投资者在季度内出售了 18,134 股后，持有 37,434 股该医疗研究公司的股票。Banque Transatlantique SA 在爱德华生命科学的持股在最近的报告期末价值为 2,907,000 美元。</p>
<p>获取 <strong>爱德华生命科学</strong> 的提醒：</p>
<ul>
<li>深入分析医疗行业收益：AZN vs. EW vs. ZBH</li>
</ul>
<p>其他对冲基金也买卖了该公司的股票。Fjarde AP Fonden Fourth Swedish National Pension Fund 在第三季度将其在爱德华生命科学的持股增加了 7.0%。Fjarde AP Fonden Fourth Swedish National Pension Fund 现在拥有 137,835 股该医疗研究公司的股票，价值 10,719,000 美元，此前在上个季度额外购买了 9,069 股。Mirae Asset Global Investments Co. Ltd.在第三季度将其在爱德华生命科学的持股增加了 13.2%。Mirae Asset Global Investments Co. Ltd.现在拥有 86,235 股该医疗研究公司的股票，价值 6,706,000 美元，此前在上个季度额外购买了 10,078 股。Atlantic Union Bankshares Corp 在第三季度将其在爱德华生命科学的持股增加了 2,240.9%。Atlantic Union Bankshares Corp 现在拥有 11,892 股该医疗研究公司的股票，价值 925,000 美元，此前在上个季度额外购买了 11,384 股。OMERS ADMINISTRATION Corp 在第二季度将其在爱德华生命科学的持股增加了 97.3%。OMERS ADMINISTRATION Corp 现在拥有 44,504 股该医疗研究公司的股票，价值 3,481,000 美元，此前在上个季度额外购买了 21,950 股。最后，纽约梅隆银行在第三季度将其在爱德华生命科学的持股增加了 8.1%。纽约梅隆银行现在拥有 19,010,227 股该医疗研究公司的股票，价值 1,478,425,000 美元，此前在上个季度额外购买了 1,423,365 股。79.46% 的股票由机构投资者持有。</p>
<h2>爱德华生命科学股票下跌 3.3%</h2>
<p>NYSE:EW 的股票在周五开盘价为 81.82 美元。该公司的市值为 475.2 亿美元，市盈率为 44.71，市盈率/增长比率为 2.21，贝塔值为 0.93。爱德华生命科学公司的 12 个月低点为 65.94 美元，12 个月高点为 87.89 美元。该公司的 50 日简单移动平均线为 82.41 美元，200 日简单移动平均线为 81.58 美元。公司快速比率为 3.09，流动比率为 3.72，债务与股本比率为 0.06。</p>
<ul>
<li>超越生物技术——3 只适合成长型投资者的医疗股票</li>
</ul>
<p>爱德华生命科学（NYSE:EW - 获取免费报告）最近在 2 月 10 日（星期二）发布了季度财报。该医疗研究公司报告季度每股收益为 0.58 美元，低于分析师一致预期的 0.62 美元，差距为 0.04 美元。该公司在季度内的收入为 15.7 亿美元，而分析师预期为 15.4 亿美元。爱德华生命科学的股本回报率为 14.50%，净利润率为 17.69%。与去年同期相比，爱德华生命科学的收入增长了 13.3%。在去年同期，该公司每股收益为 0.59 美元。爱德华生命科学已将其 2026 年第一季度的指导目标设定为 0.700-0.760 美元每股收益。分析师预测爱德华生命科学公司今年的每股收益将达到 2.45 美元。</p>
<h2>内部人士买卖情况</h2>
<p>在其他新闻中，副总裁 Daniel J. Lippis 在 3 月 11 日（星期三）出售了 1,019 股公司的股票。该股票以平均 85.38 美元的价格出售，总价值为 87,002.22 美元。交易后，副总裁直接持有 33,934 股公司的股票，价值为 2,897,284.92 美元。此次交易使其持股减少了 2.92%。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，副总裁 Donald E. Bobo, Jr.在 2 月 25 日（星期三）出售了 24,000 股公司的股票。该股票以平均 83.84 美元的价格出售，总价值为 2,012,160.00 美元。出售后，副总裁在公司中持有 21,266 股，价值约为 1,782,941.44 美元。此次交易使其持股减少了 53.02%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在上个季度出售了 61,718 股公司股票，价值为 5,236,281 美元。内部人士持有公司股票的 1.29%。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>3 只具有长期顺风的医疗行业开拓者</li>
</ul>
<p>EW 已成为多份研究分析师报告的主题。BTIG Research 在 2 月 11 日（星期三）重新发布了 “买入” 评级，并将爱德华生命科学的目标价设定为 103.00 美元。Robert W. Baird 在 1 月 12 日（星期一）设定了爱德华生命科学的目标价为 90.00 美元。花旗集团在 12 月 11 日（星期四）重新发布了 “买入” 评级，并将爱德华生命科学的目标价从 96.00 美元上调至 101.00 美元。TD Cowen 在 1 月 9 日（星期五）将爱德华生命科学的评级从 “持有” 上调至 “买入”。最后，摩根大通将爱德华生命科学的评级从 “中性” 上调至 “增持”，并将该股票的目标价从 90.00 美元上调至 100.00 美元。三位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com，该公司目前的平均评级为 “适度买入”，平均目标价为 96.14 美元。</p>
<p><strong>获取我们对爱德华生命科学的最新分析</strong></p>
<h2>爱德华生命科学简介</h2>
<p>（免费报告）</p>
<p>爱德华生命科学是一家医疗技术公司，专注于结构性心脏病和重症监护的产品和疗法。该公司设计、开发和制造用于外科手术和微创（经导管）程序的心脏瓣膜及相关输送系统。其产品组合涵盖多种瓣膜疾病，重点是能够进行经导管主动脉瓣置换（TAVR）作为开放心脏手术替代方案的技术。</p>
<p>除了经导管心脏瓣膜——包括广为人知的 SAPIEN 系列——爱德华还提供外科组织瓣膜和心脏外科医生、介入心脏病专家及医院团队使用的辅助设备。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比爱德华生命科学更好的股票</li>
<li>马丁·韦斯的个人警告（请阅读）</li>
<li>SpaceX IPO 确认：今天就来认领你的股份</li>
<li>这枚硬币拥有一切优势</li>
<li>今天仅限 500 人……</li>
<li>华尔街害怕的黄金图表……</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在爱德华生命科学吗？</h2>
<p>在考虑爱德华生命科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而爱德华生命科学并不在名单上。</p>
<p>虽然爱德华生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

爱德华生命科学

<p>法兰西跨大西洋银行（Banque Transatlantique SA）在第三季度减少了对爱德华生命科学（Edwards Lifesciences Corporation，NYSE:EW）的持股比例，下降幅度为 32.6%，目前持有 37,434 股，市值为 291 万美元。其他机构投资者也调整了他们的持仓，Fjarde AP Fonden 的持股增加了 7%，而大西洋联合银行（Atlantic Union Bankshares）的持仓则增加了 2,240.9%。最近，爱德华生命科学的股价下跌了 3.3%，市值为 475.2 亿美元，市盈率为 44.71。该公司报告的收入同比增长了 13.3%，但在最近的季度财报中未能达到每股收益（EPS）预期</p>

<p>Banque Transatlantique SA trimmed its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 32.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,434 shares of the medical research company's stock after selling 18,134 shares during the quarter. Banque Transatlantique SA's holdings in Edwards Lifesciences were worth $2,907,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会（SEC）提交的 13F 文件，Banque Transatlantique SA 在第三季度将其在爱德华生命科学公司（NYSE:EW - 免费报告）的持股比例削减了 32.6%。该机构投资者在季度内出售了 18,134 股后，持有 37,434 股该医疗研究公司的股票。Banque Transatlantique SA 在爱德华生命科学的持股在最近的报告期末价值为 2,907,000 美元。</p>
</div><p>Get <strong>Edwards Lifesciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>爱德华生命科学</strong> 的提醒：</p>
</div><ul>
<li>A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH</li>
</ul>
<div class="lb-trans"><ul>
<li>深入分析医疗行业收益：AZN vs. EW vs. ZBH</li>
</ul>
</div><p>Other hedge funds have also bought and sold shares of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company's stock worth $10,719,000 after buying an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Edwards Lifesciences by 13.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company's stock valued at $6,706,000 after acquiring an additional 10,078 shares during the last quarter. Atlantic Union Bankshares Corp raised its position in Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company's stock valued at $925,000 after purchasing an additional 11,384 shares in the last quarter. OMERS ADMINISTRATION Corp lifted its stake in Edwards Lifesciences by 97.3% during the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company's stock worth $3,481,000 after purchasing an additional 21,950 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares during the last quarter. 79.46% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金也买卖了该公司的股票。Fjarde AP Fonden Fourth Swedish National Pension Fund 在第三季度将其在爱德华生命科学的持股增加了 7.0%。Fjarde AP Fonden Fourth Swedish National Pension Fund 现在拥有 137,835 股该医疗研究公司的股票，价值 10,719,000 美元，此前在上个季度额外购买了 9,069 股。Mirae Asset Global Investments Co. Ltd.在第三季度将其在爱德华生命科学的持股增加了 13.2%。Mirae Asset Global Investments Co. Ltd.现在拥有 86,235 股该医疗研究公司的股票，价值 6,706,000 美元，此前在上个季度额外购买了 10,078 股。Atlantic Union Bankshares Corp 在第三季度将其在爱德华生命科学的持股增加了 2,240.9%。Atlantic Union Bankshares Corp 现在拥有 11,892 股该医疗研究公司的股票，价值 925,000 美元，此前在上个季度额外购买了 11,384 股。OMERS ADMINISTRATION Corp 在第二季度将其在爱德华生命科学的持股增加了 97.3%。OMERS ADMINISTRATION Corp 现在拥有 44,504 股该医疗研究公司的股票，价值 3,481,000 美元，此前在上个季度额外购买了 21,950 股。最后，纽约梅隆银行在第三季度将其在爱德华生命科学的持股增加了 8.1%。纽约梅隆银行现在拥有 19,010,227 股该医疗研究公司的股票，价值 1,478,425,000 美元，此前在上个季度额外购买了 1,423,365 股。79.46% 的股票由机构投资者持有。</p>
</div><h2>Edwards Lifesciences Stock Down 3.3%</h2>
<div class="lb-trans"><h2>爱德华生命科学股票下跌 3.3%</h2>
</div><p>Shares of NYSE:EW opened at $81.82 on Friday. The firm has a market cap of $47.52 billion, a P/E ratio of 44.71, a P/E/G ratio of 2.21 and a beta of 0.93. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The business has a fifty day simple moving average of $82.41 and a 200 day simple moving average of $81.58. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06.</p>
<div class="lb-trans"><p>NYSE:EW 的股票在周五开盘价为 81.82 美元。该公司的市值为 475.2 亿美元，市盈率为 44.71，市盈率/增长比率为 2.21，贝塔值为 0.93。爱德华生命科学公司的 12 个月低点为 65.94 美元，12 个月高点为 87.89 美元。该公司的 50 日简单移动平均线为 82.41 美元，200 日简单移动平均线为 81.58 美元。公司快速比率为 3.09，流动比率为 3.72，债务与股本比率为 0.06。</p>
</div><ul>
<li>Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>超越生物技术——3 只适合成长型投资者的医疗股票</li>
</ul>
</div><p>Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences's revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.</p>
<div class="lb-trans"><p>爱德华生命科学（NYSE:EW - 获取免费报告）最近在 2 月 10 日（星期二）发布了季度财报。该医疗研究公司报告季度每股收益为 0.58 美元，低于分析师一致预期的 0.62 美元，差距为 0.04 美元。该公司在季度内的收入为 15.7 亿美元，而分析师预期为 15.4 亿美元。爱德华生命科学的股本回报率为 14.50%，净利润率为 17.69%。与去年同期相比，爱德华生命科学的收入增长了 13.3%。在去年同期，该公司每股收益为 0.59 美元。爱德华生命科学已将其 2026 年第一季度的指导目标设定为 0.700-0.760 美元每股收益。分析师预测爱德华生命科学公司今年的每股收益将达到 2.45 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖情况</h2>
</div><p>In other news, VP Daniel J. Lippis sold 1,019 shares of the business's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares of the company's stock, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the company's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the sale, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,718 shares of company stock valued at $5,236,281 over the last quarter. Insiders own 1.29% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，副总裁 Daniel J. Lippis 在 3 月 11 日（星期三）出售了 1,019 股公司的股票。该股票以平均 85.38 美元的价格出售，总价值为 87,002.22 美元。交易后，副总裁直接持有 33,934 股公司的股票，价值为 2,897,284.92 美元。此次交易使其持股减少了 2.92%。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，副总裁 Donald E. Bobo, Jr.在 2 月 25 日（星期三）出售了 24,000 股公司的股票。该股票以平均 83.84 美元的价格出售，总价值为 2,012,160.00 美元。出售后，副总裁在公司中持有 21,266 股，价值约为 1,782,941.44 美元。此次交易使其持股减少了 53.02%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在上个季度出售了 61,718 股公司股票，价值为 5,236,281 美元。内部人士持有公司股票的 1.29%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>3 Healthcare Pathbreakers With Long-Term Tailwinds</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只具有长期顺风的医疗行业开拓者</li>
</ul>
</div><p>EW has been the subject of a number of research analyst reports. BTIG Research reissued a &#34;buy&#34; rating and set a $103.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research note on Monday, January 12th. Citigroup reissued a &#34;buy&#34; rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. TD Cowen raised shares of Edwards Lifesciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Friday, January 9th. Finally, JPMorgan Chase &amp; Co. upgraded shares of Edwards Lifesciences from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and upped their price objective for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $96.14.</p>
<div class="lb-trans"><p>EW 已成为多份研究分析师报告的主题。BTIG Research 在 2 月 11 日（星期三）重新发布了 “买入” 评级，并将爱德华生命科学的目标价设定为 103.00 美元。Robert W. Baird 在 1 月 12 日（星期一）设定了爱德华生命科学的目标价为 90.00 美元。花旗集团在 12 月 11 日（星期四）重新发布了 “买入” 评级，并将爱德华生命科学的目标价从 96.00 美元上调至 101.00 美元。TD Cowen 在 1 月 9 日（星期五）将爱德华生命科学的评级从 “持有” 上调至 “买入”。最后，摩根大通将爱德华生命科学的评级从 “中性” 上调至 “增持”，并将该股票的目标价从 90.00 美元上调至 100.00 美元。三位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com，该公司目前的平均评级为 “适度买入”，平均目标价为 96.14 美元。</p>
</div><p><strong>Get Our Latest Analysis on Edwards Lifesciences</strong></p>
<div class="lb-trans"><p><strong>获取我们对爱德华生命科学的最新分析</strong></p>
</div><h2>Edwards Lifesciences Profile</h2>
<div class="lb-trans"><h2>爱德华生命科学简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.</p>
<div class="lb-trans"><p>爱德华生命科学是一家医疗技术公司，专注于结构性心脏病和重症监护的产品和疗法。该公司设计、开发和制造用于外科手术和微创（经导管）程序的心脏瓣膜及相关输送系统。其产品组合涵盖多种瓣膜疾病，重点是能够进行经导管主动脉瓣置换（TAVR）作为开放心脏手术替代方案的技术。</p>
</div><p>In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.</p>
<div class="lb-trans"><p>除了经导管心脏瓣膜——包括广为人知的 SAPIEN 系列——爱德华还提供外科组织瓣膜和心脏外科医生、介入心脏病专家及医院团队使用的辅助设备。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Edwards Lifesciences</li>
<li>A personal warning from Martin Weiss (Please read)</li>
<li>SpaceX IPO Confirmed: Claim Your Stake Today</li>
<li>This coin has everything going for it</li>
<li>Only 500 people today…</li>
<li>The gold chart Wall Street is terrified of…</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比爱德华生命科学更好的股票</li>
<li>马丁·韦斯的个人警告（请阅读）</li>
<li>SpaceX IPO 确认：今天就来认领你的股份</li>
<li>这枚硬币拥有一切优势</li>
<li>今天仅限 500 人……</li>
<li>华尔街害怕的黄金图表……</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=EW"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Edwards Lifesciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在爱德华生命科学吗？</h2>
</div><p>Before you consider Edwards Lifesciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑爱德华生命科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而爱德华生命科学并不在名单上。</p>
</div><p>While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然爱德华生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Banque Transatlantique SA 在爱德华生命科学公司持有 291 万美元的股份